Savara Inc Realized Gains on Marketable Securities
Savara Inc (SVRA) reported Realized Gains on Marketable Securities of $0 for the 3-month period ending 2013-09-30, per its 10-Q filed 2013-11-04.
Discontinued › Income Statement › Other Income
us-gaap:MarketableSecuritiesRealizedGainLoss · last filed 2013-11-04
- Savara Inc marketable securities, realized gain (loss) for the quarter ending 2013-09-30 was $0.00.
- Savara Inc marketable securities, realized gain (loss) for the quarter ending 2013-06-30 was $0.00.
- Savara Inc marketable securities, realized gain (loss) for the quarter ending 2013-03-31 was $0.00.
| Period end | Marketable Securities, Realized Gain (Loss) 3 month | Marketable Securities, Realized Gain (Loss) 6 month | Marketable Securities, Realized Gain (Loss) 9 month |
|---|---|---|---|
| 2013-09-30 | $0.00 10-Q · filed 2013-11-04 | $0.00 derived: sum of 2 quarters · filed 2013-11-04 | $0.00 derived: sum of 3 quarters · filed 2013-11-04 |
| 2013-06-30 | $0.00 10-Q · filed 2013-08-05 | $0.00 derived: sum of 2 quarters · filed 2013-08-05 | |
| 2013-03-31 | $0.00 10-Q · filed 2013-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |